ID

25533

Beschrijving

A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00467649

Link

https://clinicaltrials.gov/show/NCT00467649

Trefwoorden

  1. 05-09-17 05-09-17 -
Geüploaded op

5 september 2017

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0

Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Type 2 Diabetes Mellitus NCT00467649

Eligibility Type 2 Diabetes Mellitus NCT00467649

Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
has a clinical diagnosis of type 2 diabetes mellitus
Beschrijving

Diabetes Mellitus, Non-Insulin-Dependent

Datatype

boolean

Alias
UMLS CUI [1]
C0011860
has an hba1c >7.0% and ≤10.0%
Beschrijving

Glycosylated hemoglobin A

Datatype

boolean

Alias
UMLS CUI [1]
C0019018
has a bmi of ≥25 kg/m^2 and ≤50 kg/m^2
Beschrijving

Body mass index

Datatype

boolean

Alias
UMLS CUI [1]
C1305855
has been on a regimen of insulin for less than 6 months and is taking less than 50 u total of insulin per day, or has not been on a pre existing insulin regimen and is a candidate for the initiation of basal insulin therapy
Beschrijving

Insulin regime | Insulin U/day | Insulin regime Pre-existing Absent | Patient Appropriate Initiation Basal insulin

Datatype

boolean

Alias
UMLS CUI [1]
C0557978
UMLS CUI [2,1]
C0021641
UMLS CUI [2,2]
C0456683
UMLS CUI [3,1]
C0557978
UMLS CUI [3,2]
C2347662
UMLS CUI [3,3]
C0332197
UMLS CUI [4,1]
C0030705
UMLS CUI [4,2]
C1548787
UMLS CUI [4,3]
C1704686
UMLS CUI [4,4]
C0650607
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
has experienced recurrent severe hypoglycemia requiring assistance during the past 6 months
Beschrijving

Recurrent severe hypoglycemia Treatment required for

Datatype

boolean

Alias
UMLS CUI [1,1]
C0342316
UMLS CUI [1,2]
C0332121
requires the use of drugs that stimulate gastrointestinal motility
Beschrijving

Requirement Pharmaceutical Preparations Stimulating Gastrointestinal Motility

Datatype

boolean

Alias
UMLS CUI [1,1]
C1514873
UMLS CUI [1,2]
C0013227
UMLS CUI [1,3]
C1948023
UMLS CUI [1,4]
C0017184
has been previously treated with symlin (or has participated in a symlin clinical study)
Beschrijving

Symlin | Study Subject Participation Status

Datatype

boolean

Alias
UMLS CUI [1]
C1174780
UMLS CUI [2]
C2348568
is currently being treated with any of the following medications: *over-the-counter antiobesity agents (including, but not limited to, herbal supplements) or prescription antiobesity agents (including orlistat [xenical®] and sibutramine [meridia®]); *oral, intravenous, or intramuscular systemic steroids by oral or potent inhaled or intrapulmonary steroids that are known to have a high rate of systemic absorption; *drugs that directly affect gastrointestinal motility, including but not limited to: dopamine antagonists (e.g., metoclopramide [reglan®]), opiates or anticholinergics; and chronic (more than 10 days within a 6-month period) macrolide antibiotics such as erythromycin and newer derivatives; *investigational medications
Beschrijving

Anti-Obesity Agents Non-Prescription | Herbal supplement | Anti-Obesity Agents | orlistat | Xenical | sibutramine | Meridia | Systemic steroids Oral | Systemic steroids Intravenous | Systemic steroids Intramuscular | Steroids Oral | inhaled steroids | Steroids Intrapulmonary | Systemic Absorption Rate High | Pharmaceutical Preparations Affecting Gastrointestinal Motility | Dopamine Antagonists | Metoclopramide | Reglan | Opiates | Anticholinergic Agents | Macrolide Antibiotics chronic | Erythromycin | Erythromycin Derivative | Investigational New Drugs

Datatype

boolean

Alias
UMLS CUI [1,1]
C0376607
UMLS CUI [1,2]
C0013231
UMLS CUI [2]
C1504473
UMLS CUI [3]
C0376607
UMLS CUI [4]
C0076275
UMLS CUI [5]
C0732649
UMLS CUI [6]
C0074493
UMLS CUI [7]
C0635898
UMLS CUI [8,1]
C2825233
UMLS CUI [8,2]
C1527415
UMLS CUI [9,1]
C2825233
UMLS CUI [9,2]
C1522726
UMLS CUI [10,1]
C2825233
UMLS CUI [10,2]
C1556154
UMLS CUI [11,1]
C0038317
UMLS CUI [11,2]
C1527415
UMLS CUI [12]
C2065041
UMLS CUI [13,1]
C0038317
UMLS CUI [13,2]
C1522224
UMLS CUI [14,1]
C3850076
UMLS CUI [14,2]
C1521828
UMLS CUI [14,3]
C0205250
UMLS CUI [15,1]
C0013227
UMLS CUI [15,2]
C0392760
UMLS CUI [15,3]
C0017184
UMLS CUI [16]
C0242702
UMLS CUI [17]
C0025853
UMLS CUI [18]
C0034977
UMLS CUI [19]
C0376196
UMLS CUI [20]
C0242896
UMLS CUI [21,1]
C0003240
UMLS CUI [21,2]
C0205191
UMLS CUI [22]
C0014806
UMLS CUI [23,1]
C0014806
UMLS CUI [23,2]
C1527240
UMLS CUI [24]
C0013230
has a history or presence of any of the following: *eating disorders (including anorexia and/or bulimia); *bariatric surgery (gastric bypass, gastric banding, or gastroplasty)
Beschrijving

Eating Disorders | Anorexia | Bulimia | Bariatric Surgery | Gastric Bypass | Partitioning of stomach using band | Gastroplasty

Datatype

boolean

Alias
UMLS CUI [1]
C0013473
UMLS CUI [2]
C0003123
UMLS CUI [3]
C0006370
UMLS CUI [4]
C1456587
UMLS CUI [5]
C0017125
UMLS CUI [6]
C1960832
UMLS CUI [7]
C0017193
is currently enrolled in a weight-loss program or plans to enroll in a weight-loss program before termination of the study
Beschrijving

Enrollment Weight Reduction Program | Enrollment Weight Reduction Program Planned

Datatype

boolean

Alias
UMLS CUI [1,1]
C1516879
UMLS CUI [1,2]
C3179079
UMLS CUI [2,1]
C1516879
UMLS CUI [2,2]
C3179079
UMLS CUI [2,3]
C1301732
has donated blood within 30 days of study start or plans to donate blood during the duration of the study
Beschrijving

Blood Donation | Blood Donation Planned

Datatype

boolean

Alias
UMLS CUI [1]
C0005794
UMLS CUI [2,1]
C0005794
UMLS CUI [2,2]
C1301732

Similar models

Eligibility Type 2 Diabetes Mellitus NCT00467649

Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent
Item
has a clinical diagnosis of type 2 diabetes mellitus
boolean
C0011860 (UMLS CUI [1])
Glycosylated hemoglobin A
Item
has an hba1c >7.0% and ≤10.0%
boolean
C0019018 (UMLS CUI [1])
Body mass index
Item
has a bmi of ≥25 kg/m^2 and ≤50 kg/m^2
boolean
C1305855 (UMLS CUI [1])
Insulin regime | Insulin U/day | Insulin regime Pre-existing Absent | Patient Appropriate Initiation Basal insulin
Item
has been on a regimen of insulin for less than 6 months and is taking less than 50 u total of insulin per day, or has not been on a pre existing insulin regimen and is a candidate for the initiation of basal insulin therapy
boolean
C0557978 (UMLS CUI [1])
C0021641 (UMLS CUI [2,1])
C0456683 (UMLS CUI [2,2])
C0557978 (UMLS CUI [3,1])
C2347662 (UMLS CUI [3,2])
C0332197 (UMLS CUI [3,3])
C0030705 (UMLS CUI [4,1])
C1548787 (UMLS CUI [4,2])
C1704686 (UMLS CUI [4,3])
C0650607 (UMLS CUI [4,4])
Item Group
C0680251 (UMLS CUI)
Recurrent severe hypoglycemia Treatment required for
Item
has experienced recurrent severe hypoglycemia requiring assistance during the past 6 months
boolean
C0342316 (UMLS CUI [1,1])
C0332121 (UMLS CUI [1,2])
Requirement Pharmaceutical Preparations Stimulating Gastrointestinal Motility
Item
requires the use of drugs that stimulate gastrointestinal motility
boolean
C1514873 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
C1948023 (UMLS CUI [1,3])
C0017184 (UMLS CUI [1,4])
Symlin | Study Subject Participation Status
Item
has been previously treated with symlin (or has participated in a symlin clinical study)
boolean
C1174780 (UMLS CUI [1])
C2348568 (UMLS CUI [2])
Anti-Obesity Agents Non-Prescription | Herbal supplement | Anti-Obesity Agents | orlistat | Xenical | sibutramine | Meridia | Systemic steroids Oral | Systemic steroids Intravenous | Systemic steroids Intramuscular | Steroids Oral | inhaled steroids | Steroids Intrapulmonary | Systemic Absorption Rate High | Pharmaceutical Preparations Affecting Gastrointestinal Motility | Dopamine Antagonists | Metoclopramide | Reglan | Opiates | Anticholinergic Agents | Macrolide Antibiotics chronic | Erythromycin | Erythromycin Derivative | Investigational New Drugs
Item
is currently being treated with any of the following medications: *over-the-counter antiobesity agents (including, but not limited to, herbal supplements) or prescription antiobesity agents (including orlistat [xenical®] and sibutramine [meridia®]); *oral, intravenous, or intramuscular systemic steroids by oral or potent inhaled or intrapulmonary steroids that are known to have a high rate of systemic absorption; *drugs that directly affect gastrointestinal motility, including but not limited to: dopamine antagonists (e.g., metoclopramide [reglan®]), opiates or anticholinergics; and chronic (more than 10 days within a 6-month period) macrolide antibiotics such as erythromycin and newer derivatives; *investigational medications
boolean
C0376607 (UMLS CUI [1,1])
C0013231 (UMLS CUI [1,2])
C1504473 (UMLS CUI [2])
C0376607 (UMLS CUI [3])
C0076275 (UMLS CUI [4])
C0732649 (UMLS CUI [5])
C0074493 (UMLS CUI [6])
C0635898 (UMLS CUI [7])
C2825233 (UMLS CUI [8,1])
C1527415 (UMLS CUI [8,2])
C2825233 (UMLS CUI [9,1])
C1522726 (UMLS CUI [9,2])
C2825233 (UMLS CUI [10,1])
C1556154 (UMLS CUI [10,2])
C0038317 (UMLS CUI [11,1])
C1527415 (UMLS CUI [11,2])
C2065041 (UMLS CUI [12])
C0038317 (UMLS CUI [13,1])
C1522224 (UMLS CUI [13,2])
C3850076 (UMLS CUI [14,1])
C1521828 (UMLS CUI [14,2])
C0205250 (UMLS CUI [14,3])
C0013227 (UMLS CUI [15,1])
C0392760 (UMLS CUI [15,2])
C0017184 (UMLS CUI [15,3])
C0242702 (UMLS CUI [16])
C0025853 (UMLS CUI [17])
C0034977 (UMLS CUI [18])
C0376196 (UMLS CUI [19])
C0242896 (UMLS CUI [20])
C0003240 (UMLS CUI [21,1])
C0205191 (UMLS CUI [21,2])
C0014806 (UMLS CUI [22])
C0014806 (UMLS CUI [23,1])
C1527240 (UMLS CUI [23,2])
C0013230 (UMLS CUI [24])
Eating Disorders | Anorexia | Bulimia | Bariatric Surgery | Gastric Bypass | Partitioning of stomach using band | Gastroplasty
Item
has a history or presence of any of the following: *eating disorders (including anorexia and/or bulimia); *bariatric surgery (gastric bypass, gastric banding, or gastroplasty)
boolean
C0013473 (UMLS CUI [1])
C0003123 (UMLS CUI [2])
C0006370 (UMLS CUI [3])
C1456587 (UMLS CUI [4])
C0017125 (UMLS CUI [5])
C1960832 (UMLS CUI [6])
C0017193 (UMLS CUI [7])
Enrollment Weight Reduction Program | Enrollment Weight Reduction Program Planned
Item
is currently enrolled in a weight-loss program or plans to enroll in a weight-loss program before termination of the study
boolean
C1516879 (UMLS CUI [1,1])
C3179079 (UMLS CUI [1,2])
C1516879 (UMLS CUI [2,1])
C3179079 (UMLS CUI [2,2])
C1301732 (UMLS CUI [2,3])
Blood Donation | Blood Donation Planned
Item
has donated blood within 30 days of study start or plans to donate blood during the duration of the study
boolean
C0005794 (UMLS CUI [1])
C0005794 (UMLS CUI [2,1])
C1301732 (UMLS CUI [2,2])

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial